Close menu




June 16th, 2020 | 06:30 CEST

Gilead, Teva, XPhyto - Global marketing potential

  • Healthcare
Photo credits: pixabay.com

The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.

time to read: 2 minutes | Author: Mario Hose
ISIN: CA98421R1055 , US8816242098 , US3755581036

Table of contents:


    Thin Film Solutions for a Mass Market

    XPhyto from Canada announced yesterday that its German subsidiary Vektor Pharma TF GmbH has successfully incorporated peptide biosensors into the group's oral dissolvable thin film (ODF) technology. Together with its partner 3a-Diagnostics GmbH, the company is now developing pathogen-specific ODF biosensors for infectious diseases, including pandemic threats, the company announced.

    "Successful incorporation of 3a's peptide biosensors into Vektor's ODF platform represents a significant technical milestone on the pathway to commercialization," Hugh Rogers, XPhyto CEO said in a statement. "This was a critical step that unlocks a pipeline of potential biosensor screening products."

    3a biosensor screening tests have been developed for bacterial and viral infectious diseases, including influenza A, scarlet fever and periodontitis. The market is therefore large and further pandemic-focused biosensors are planned and developed, especially for coronavirus, swine flu and avian flu, according to the announcement. The partnership at product level therefore has potential. The market value of XPhyto is EUR 115.1 million.

    Products for the Chinese market

    Teva recently announced that the Chinese Food and Drug Administration has approved Austedo for the treatment of chorea associated with Huntington's disease and late dyskinesia in adults. According to the announcement, the company will independently market the drug Austedo in China. This follows the launch of the specialty drug Treanda on the Chinese market.

    "We look forward to bringing more of the essential medicines in our portfolio to patients in China, and to fuel organic growth and expand our presence in this important market," said Gianfranco Nazzi of Teva, who is responsible for international markets. The market value of the company is around EUR 10.9 billion.

    Licensing for 127 countries

    Last week Gilead signed a license agreement with Dr. Reddy's Laboratories Ltd. for the registration, manufacture and sale of the antiviral drug Remdesivir. The product Remdesivir became known because it can be used to treat the current coronavirus. The contract covers a total of 127 countries, but an official approval for the marketing of Remdesivir in the respective country still has to be obtained from Dr. Reddy's.

    In May 2020, the US Food and Drug Administration (FDA) granted emergency use authorization for Gilead's antiviral drug Remdesivir for the treatment of Covid-19. Under the non-exclusive license agreement, Dr. Reddy's will receive a technology transfer from Gilead for the manufacture of Remdesivir. Gilead's most recent market capitalization was approximately EUR 82.4 billion and this makes the company one of the heavyweights in the industry.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on November 23rd, 2023 | 07:20 CET

    Saturn Oil + Gas, Rheinmetall, Bayer - Energy, Defense, Healthcare: Where short-term returns await

    • Mining
    • Oil
    • defense
    • Healthcare

    In Germany, the federal government put its spending on hold, a day after the Federal Constitutional Court ruled that the reallocation of EUR 60 billion of unused debt from the pandemic era to the Energy and Climate Fund was unlawful. Europe's largest economy is shrinking due to rising energy prices and trade tensions. At the same time, North America, with stable oil companies such as Saturn Oil & Gas, presents an attractive investment opportunity for investors. Rheinmetall is experiencing a target price high of EUR 370 and flirting with long-term prospects in the US. At the same time, Bayer grapples with legal challenges and the failure of the blood thinner 'asundexian'. We look at where an investment may be worthwhile now.

    Read

    Commented by Juliane Zielonka on November 10th, 2023 | 09:15 CET

    Healthcare and Logistics in Focus with Amazon, First Hydrogen, Bayer - Where growth is created

    • Hydrogen
    • greenhydrogen
    • Logistics
    • Healthcare
    • Technology

    Telemedicine is a blessing for anyone lying in bed with a fever and in need of a doctor or medication. Now, 167 million Americans can benefit from it. Amazon rolled out the telemedicine service to all Prime members in the States this week. To ensure that deliveries arrive on time and with as few emissions as possible, First Hydrogen has developed a van that has already successfully passed its test phase in the UK. A range of 630 km can be covered on one hydrogen charge. But that is not all; the Company is planning much more in the field of hydrogen. After sobering figures, Bayer AG is focusing on drastic measures instead of innovations, but these will benefit those who truly do their job. We take a glance at the details.

    Read

    Commented by Juliane Zielonka on October 6th, 2023 | 08:00 CEST

    Cantourage Group SE, Amazon, British American Tobacco: Stockpiling between medical innovation and dividend history

    • Cannabis
    • Healthcare
    • AI

    The Berlin-based company Cantourage, which specializes in the distribution of medical cannabis, is experiencing promising growth in the booming medical cannabis market. The global market for the plant's medical use is expected to have reached around USD 12.92 billion since 2021 and is projected to grow to USD 23.97 billion by 2028 at an average CAGR of 13.16%. Cantourage continues to expand its strong international distribution network with its innovative Fast Track Access platform. The Company even has a chance to win in the "Most Innovative Business Strategy" category at the 2023 European Small and Midcap Awards in November. Unlike other medical cannabis producers, Cantourage does not grow its own plants. Just as Uber doesn't own cars and AirBnB doesn't own hotels, Cantourage relies on strong distribution power in Healthcare. Healthcare is also attractive to Amazon again. Through mergers and acquisitions involving an online pharmacy and a thriving network of doctors, the US company is now investing in generative AI beyond ChatGPT. Meanwhile, historic dividend king British American Tobacco faces decline and bans.

    Read